Adverse events leading to dose reductions were palmar-plantar erythrodysaesthesia (n = 2), abdominal pain, abdominal pain upper, diarrhea, gastritis, increased ALT, and decreased platelet count. The gene discussed is GPT; the disease is gastritis.